argenex (ARGX) Competitors $753.78 +20.12 (+2.74%) As of 11:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARGX vs. SNY, GSK, TAK, ONC, INSM, BNTX, TEVA, SMMT, GMAB, and VTRSShould you be buying argenex stock or one of its competitors? The main competitors of argenex include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. argenex vs. Its Competitors Sanofi GSK Takeda Pharmaceutical BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Sanofi (NASDAQ:SNY) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Do analysts rate SNY or ARGX? Sanofi currently has a consensus price target of $62.00, indicating a potential upside of 33.12%. argenex has a consensus price target of $772.84, indicating a potential upside of 3.26%. Given Sanofi's stronger consensus rating and higher probable upside, equities analysts plainly believe Sanofi is more favorable than argenex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 3 Strong Buy rating(s) 3.22argenex 0 Sell rating(s) 0 Hold rating(s) 21 Buy rating(s) 2 Strong Buy rating(s) 3.09 Which has higher earnings and valuation, SNY or ARGX? Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanofi$44.46B2.57$6.02B$4.1611.20argenex$2.25B20.34$833.04M$19.5038.38 Does the media favor SNY or ARGX? In the previous week, argenex had 4 more articles in the media than Sanofi. MarketBeat recorded 27 mentions for argenex and 23 mentions for Sanofi. argenex's average media sentiment score of 1.27 beat Sanofi's score of 0.64 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 10 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive argenex 22 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SNY or ARGX more profitable? argenex has a net margin of 40.98% compared to Sanofi's net margin of 21.47%. argenex's return on equity of 21.06% beat Sanofi's return on equity.Company Net Margins Return on Equity Return on Assets Sanofi21.47% 16.86% 9.63% argenex 40.98%21.06%18.25% Which has more volatility & risk, SNY or ARGX? Sanofi has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, argenex has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Do insiders & institutionals believe in SNY or ARGX? 14.0% of Sanofi shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Summaryargenex beats Sanofi on 11 of the 17 factors compared between the two stocks. Get argenex News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARGX vs. The Competition Export to ExcelMetricargenexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.69B$3.15B$5.77B$9.87BDividend YieldN/A2.28%6.67%4.51%P/E Ratio38.2821.0975.6126.46Price / Sales20.34471.78551.64120.26Price / Cash243.0645.1137.1158.92Price / Book8.279.7711.536.02Net Income$833.04M-$53.47M$3.29B$266.38M7 Day Performance5.09%0.91%-0.12%-0.53%1 Month Performance10.90%6.59%6.12%3.30%1 Year Performance36.46%11.62%60.95%22.81% argenex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARGXargenex4.0653 of 5 stars$748.45+2.0%$772.84+3.3%+39.1%$45.69B$2.25B38.281,599Positive NewsAnalyst ForecastSNYSanofi3.7552 of 5 stars$49.48-0.9%$62.00+25.3%-22.6%$121.50B$45.74B11.8982,878Trending NewsAnalyst UpgradeShort Interest ↑Gap UpGSKGSK2.7871 of 5 stars$39.68+0.6%$37.38-5.8%-10.6%$80.82B$40.10B18.3768,629Positive NewsDividend CutAnalyst RevisionTAKTakeda Pharmaceutical2.6763 of 5 stars$14.99+0.1%N/A+2.1%$47.68B$4.48T49.9547,455Positive NewsONCBeOne Medicines0.798 of 5 stars$306.05+2.7%$330.89+8.1%N/A$33.54B$4.56B-176.9111,000Gap UpINSMInsmed3.7906 of 5 stars$136.10+0.8%$132.57-2.6%+89.4%$28.77B$363.71M-23.841,271Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionBNTXBioNTech1.2951 of 5 stars$100.00-1.9%$135.80+35.8%+16.3%$24.04B$2.88B-62.506,772Positive NewsGap UpTEVATeva Pharmaceutical Industries3.4182 of 5 stars$18.41+2.0%$24.71+34.3%-2.3%$21.11B$16.54B-115.0436,830News CoveragePositive NewsSMMTSummit Therapeutics3.3516 of 5 stars$23.70-2.9%$33.31+40.5%+98.3%$17.61B$700K-23.47110News CoverageAnalyst ForecastOptions VolumeGap UpGMABGenmab A/S4.0739 of 5 stars$24.87-1.0%$37.60+51.2%-0.8%$15.96B$3.26B12.502,682Positive NewsVTRSViatris1.7947 of 5 stars$10.55+1.3%$10.40-1.4%-12.3%$12.30B$14.12B-3.6432,000 Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives ONC Alternatives INSM Alternatives BNTX Alternatives TEVA Alternatives SMMT Alternatives GMAB Alternatives VTRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARGX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenex SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
